On the frontline: pediatric obesity in the emergency department

Heather M Prendergast1, Matthew Close, Brett Jones

  • 1University of Illinois, Department of Emergency Medicine, 808 S Wood, Rm 471-H M/C 722, Chicago, IL 60612, USA. hprender.heather@gmail.com

Insights

Childhood obesity is a growing concern. This study found higher rates of overweight and obesity in a minority pediatric population compared to national averages, highlighting the need for intervention.

Area of Science:

  • Pediatric Emergency Medicine
  • Public Health
  • Obesity Research

Background:

  • Childhood obesity rates are increasing globally.
  • Pediatric emergency departments (EDs) serve a high-risk population.
  • Existing data on weight status in ED pediatric patients is limited.

Purpose of the Study:

  • To determine the prevalence of normal weight, overweight, and obesity in pediatric ED visits.
  • To characterize discharge diagnoses and service levels by weight category.
  • To compare weight status in a minority pediatric population to national rates.

Main Methods:

  • Retrospective review of electronic ED medical and billing records.
  • Inclusion criteria: children aged 2-17 years.
  • Body Mass Index (BMI) and percentiles calculated using CDC formulas; overweight (85th-94th percentile), obesity (>95th percentile).

Main Results:

  • 46% of 596 pediatric ED patients were overweight or obese.
  • Overweight/obesity rates were similar across racial/ethnic groups, with slight predominance in minorities.
  • No significant differences in discharge diagnosis or level of service by weight category.
  • Overweight and obesity rates exceeded published national rates in this population.

Conclusions:

  • Pediatric EDs encounter high rates of overweight and obesity, particularly in minority populations.
  • EDs represent an untapped resource for childhood obesity screening and referral.
  • Innovative strategies are needed to address the childhood obesity epidemic.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...